Comparison
R-Phenylpiracetam vs Phenylpiracetam
Enantiopure drive vs. racemic balance: cleaner dopamine targeting or time-tested racetam stimulant.
R-Phenylpiracetam
Selective Dopamine Transporter (DAT) Inhibitor
Phenylpiracetam
Stimulant Racetam / DAT Inhibitor
Effectiveness Profile
At a Glance
| R-Phenylpiracetam | Phenylpiracetam | |
|---|---|---|
| Type | Nootropic | Nootropic |
| Legal status | Research | Grey-Market |
| Half-life | 2–5 hours | 3–5 hours |
| Preferred route | Oral | Oral |
| Dose frequency | as-needed | as-needed |
| Beginner dose | 50–75 mg | 100–100 mg |
| Intermediate dose | 75–100 mg | 100–200 mg |
| Advanced dose | 100–150 mg | 200–300 mg |
| Cycle length | 1–4 wks | 1–4 wks |
| Bioavailability | 65% | 100% |
| Time to peak | 0.5h | 1h |
| Active duration | 6h | 6h |
| Storage | Room temperature, dry, away from light | Room temperature, dry, away from light |
| PCT required | No | No |
| Ancillaries required | No | No |
| Safe for women | Yes | Yes |
Verdict
R-Phenylpiracetam wins for: Dopamine transporter selectivity, potency-per-mg, predictable focus/drive, reduced off-target CNS action, and minimized fluff from inert isomer. For research requiring pure dopaminergic push without excess peripheral effects, R-PhP is the cleaner instrument.
Phenylpiracetam wins for: Availability, established background data, slightly more rounded effect profile (including mild cholinergic activity), and usually lower cost per active mg due to wider distribution. Its mix of enantiomers brings broader—but less pinpointed—effects, often favored where full racetam familiarity and legacy supply chains matter.
Pick A or B?
Pick R-Phenylpiracetam if:
- The protocol demands maximal dopaminergic drive with minimal off-target effects (cleaner CNS activation)
- Event-driven focus for high-stakes output (peak training, deep-work sprints, demanding cold-endurance protocols)
- Tolerance mitigation is top priority (lower mg dosage achieves target effect)
- Purity and identity of compound can be guaranteed (reputable research supplier)
- Research design specifically calls for the (R)-enantiomer profile/kinetics
Pick Phenylpiracetam if:
- Proven outcome data across many years and user reports is important (legacy as Phenotropil)
- Cost-efficiency and ease of sourcing are key considerations
- A slightly broader CNS effect—cholinergic plus dopaminergic—is desirable
- Supply chain or regulatory context favors established, racemic materials
- The protocol can tolerate minor variability from the inactive isomer (D-form)